The present invention relates to the use of at least one compound comprisingthe amino acid sequence:(X1)n X2X3PVX4X5X6(X7)m (Formula I), wherein X1 is any amino acid residue, X2is an amino acid residue selected from the groupconsist ing of aspartic acid (D) and glutamic acid (E), X3 is any amino acidresidue, X4 is any amino acid residue, X5 is an aminoacid residue selected from the group consisting of proline (P) and alanine(A), X6 is an amino acid residue selected from the groupconsisting of aspartic acid (D) and glutamic acid (E), X7 is any amino acidresidue, n and m, independently, are 0 or an integer ofmore than 0, and wherein the amino acid sequence according to Formula I is notidentical with, or does not comprise the 8-merpolypeptide fragment of alpha-synuclein having the amino acid sequenceDMPVDPDN, said compound having a binding capacityto an antibody which is specific for an epitope of alpha-synuclein comprisingthe amino acid sequence DMPVDPDN forproducing a medicament for preventing and/or treating synucleinopathies.
